Joseph C. Scodari, a member of the Board of Directors since 2021, notified Acurx Pharmaceuticals of his intention to retire from the Board effective November 13, 2026. His departure is not due to any disagreement with the company, and he has agreed to continue serving as a corporate advisor following his retirement.
Acurx Pharmaceuticals reported a net loss of $6.5 million for the nine months ended September 30, 2026, compared to $6.4 million in the prior year period. The company strengthened its cash position to $9.7 million following equity issuances, while research and development expenses increased significantly in the third quarter to $1.1 million.
Acurx Pharmaceuticals held its Annual Meeting of Stockholders on October 16, 2026, where shareholders elected David P. Luci and Jack H. Dean as Class II directors for three-year terms. Additionally, stockholders ratified the appointment of CohnReznick LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.